Chemomab Therapeutics (CMMB) Stock Price, News & Analysis

Company Overview

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes. Its lead oncology programs employ novel bispecific formats intended to engage immune effector cells against solid tumors, while infectious disease programs focus on broad-spectrum neutralization of viral pathogens. Chemomab’s inflammatory disease efforts seek to modulate autoimmune pathways through highly selective receptor blockade.

Headquartered in Shanghai with a presence in the United States, Chemomab fosters global collaboration with academic institutions and contract research organizations. The company was founded by a team of immunology and protein engineering experts and is led by a management group with extensive experience in biotechnology R&D and regulatory affairs. Through strategic partnerships and disciplined clinical development, Chemomab Therapeutics is positioning itself to address significant unmet medical needs in multiple therapeutic areas.

Key Stats

• Today's Range: $2.70 to $2.99
• 50-Day Range: $2.82 to $4.68
• 52-Week Range: $2.70 to $9.84
• Volume: 52,559 shs
• Average Volume: 67,626 shs
• Market Capitalization: $14.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.50
• Consensus Rating: Buy

Chemomab Therapeutics Stock Analysis - MarketRank™

Chemomab Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 460th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Chemomab Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Chemomab Therapeutics has a consensus price target of $26.50, representing about 874.3% upside from its current price of $2.72.

Amount of Analyst Coverage

Chemomab Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Chemomab Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Chemomab Therapeutics is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chemomab Therapeutics is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Chemomab Therapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.95% of the float of Chemomab Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Chemomab Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chemomab Therapeutics has recently increased by 401.92%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Chemomab Therapeutics does not currently pay a dividend.

Dividend Growth

Chemomab Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.95% of the float of Chemomab Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Chemomab Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chemomab Therapeutics has recently increased by 401.92%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.30

News Sentiment

Chemomab Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Chemomab Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for CMMB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Chemomab Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CMMB Stock Analysis - Frequently Asked Questions

How have CMMB shares performed this year?

Chemomab Therapeutics' stock was trading at $7.24 at the start of the year. Since then, CMMB shares have decreased by 62.4% and is now trading at $2.72.

How were Chemomab Therapeutics' earnings last quarter?

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) announced its quarterly earnings results on Thursday, August, 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.44.

When did Chemomab Therapeutics' stock split?

Chemomab Therapeutics's stock reverse split before market open on Tuesday, August 26th 2025.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Who are Chemomab Therapeutics' major shareholders?

Top institutional shareholders of Chemomab Therapeutics include Orbimed Advisors LLC (4.99%). Insiders that own company stock include Israel Gp Ltd Orbimed, George Adi Mor and Neil Harris Cohen.
View institutional ownership trends.

How do I buy shares of Chemomab Therapeutics?

Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Chemomab Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Chemomab Therapeutics investors own include Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW), NVIDIA (NVDA), Meta Platforms (META) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CMMB
• CIK: 1534248
• Web: www.chemomab.com
• Phone: 972-77-331-0156
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Chemomab Therapeutics: $26.50
• High Price Target: $28.00
• Low Price Target: $25.00
• Potential Upside/Downside: +843.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -94.71%
• Return on Assets: -76.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.42
• Quick Ratio: 7.42

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.87 per share
• Price / Book: 0.98

Miscellaneous

• Outstanding Shares: 5,170,000
• Free Float: 4,557,000
• Market Cap: $14.53 million
• Optionable: Not Optionable
• Beta: 0.51